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Abstract 
Objective: Pancreas-related complications are some of the most serious ones in abdominal 
surgery. The goal of this study was to develop and validate novel near-infrared (NIR) fluorophores 
that would enable real-time pancreas imaging to avoid the intraoperative pancreatic injury. 
Design: After initial screening of a large NIR fluorophore library, the performance of 3 selected 
pancreas-targeted 700 nm NIR fluorophores, T700-H, T700-F, and MB, were quantified in mice, 
rats, and pigs. Dose ranging using 25 and 100 nmol, and 2.5 µmol of T700-F, and its imaging kinetics 
over a 4 h period were tested in each species. Three different 800 nm NIR fluorophores were 
employed for dual-channel FLARE™ imaging in pigs: 2 μmol of ZW800-1 for vessels and kidney, 1 
μmol of ZW800-3C for lymph nodes, and 2 μmol of ESNF31 for adrenal glands.  
Results: T700-F demonstrated the highest signal to background ratio (SBR), with peak SBR at 4 h 
postinjection in mice. In pigs, T700-F produced an SBR ≥ 2 against muscle, spleen, and lymph nodes 
for up to 8 h after a single intravenous injection. The combination of T700-F with each 800 nm NIR 
fluorophore provided simultaneous dual-channel intraoperative imaging of pancreas with sur-
rounding organs in real time. 
Conclusion: Pancreas-targeted NIR fluorophores combined with the FLARE dual-channel im-
aging system enable the real-time intraoperative pancreas imaging which helps surgeons perform 
safer and more curative abdominal surgeries. 
Key words: Pancreas-related complications, Postoperative pancreatic fistula, Intraoperative pan-
creatic injury, Image-guided surgery, Near-Infrared fluorescence. 
Introduction 
Pancreas-related complications in abdominal 
surgery are serious and sometimes fatal. Unrecog-
nized intraoperative pancreatic injury results in many 
pancreas-related complications, such as postoperative 
pancreatic fistulae, peripancreatic abscesses, and 
pancreatitis [1,2]. These can progress to more serious 
complications such as intra-abdominal hemorrhage 
and septic shock, which result in longer hospital stays 
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and higher medical costs [3]. The incidence of pan-
creas-related complications after gastrectomy with 
radical lymphadenectomy, which is the standard 
procedure in advanced gastric cancers, ranges from 
5.8 to 49.7% [3-8]. Even performing laparoscopic gas-
trectomy, which offers a magnified view of the sur-
gical field, reported complication rates range from 4.3 
to 7.2% [1,2]. In addition to other gastrointestinal 
surgeries such as colectomy and splenectomy [9], 
urological surgeries including nephrectomy and 
adrenalectomy also have a high risk factor of pancre-
as-related complications [10]. 
Intraoperative pancreatic injuries are typically 
caused by the proximity of the pancreas to sur-
rounding organs and the difficulty in distinguishing 
the edge of the pancreas from surrounding fat tissue, 
especially in obese patients. Real-time, high sensitiv-
ity identification of the pancreas intraoperatively 
could help avoid such injury. Previously we reported 
that near-infrared (NIR) fluorescent light could be 
used to identify both the pancreas and insulinoma by 
employing the clinically available NIR fluorophore 
methylene blue (MB) [11]. Although MB provided 
contrast between the pancreas and surrounding or-
gans, it is not an ideal NIR contrast agent because of 
low signal intensity, nonspecific uptake, and short 
retention time in the pancreas.  
Recently, we developed a library of NIR fluoro-
phores targeted to various tissues and organs includ-
ing thyroid and parathyroid [12], lymph nodes [13], 
nerves [14], adrenal glands [15], and bone [16] with 
high signal in the target and relatively low back-
ground after a single intravenous injection. Further-
more, screening the in vivo performance of our over 
300 novel compounds, we found T700-F and T700-H 
could target the pancreas specifically. Combined with 
our FLARE intraoperative imaging system, which 
provides simultaneous dual-channel NIR fluores-
cence imaging along with color video, various sur-
geries can now be performed under real-time image 
guidance [17]. In this study, we hypothesized that the 
same approach could be used for pancreas imaging, 
and focused our experiments on novel agents that 
could outperform MB.  
Materials and Methods 
NIR Fluorescent Contrast Agents: Methylene 
blue (MB; USP 1%, 10 mg/mL) was purchased from 
Taylor Pharmaceuticals (Decatur, IL). T700-H and 
T700-F were synthesized as described in our previous 
reports [12,18-20], and served as pancreas targeting 
700 nm emitting NIR fluorophores. Three different 
800 nm NIR fluorophores including ZW800-1, 
ZW800-3C, and ESNF31, were also used for the dual 
channel imaging of surrounding tissue: ZW800-1 for 
NIR angiography and kidney imaging [21]; 
ZW800-3C for PLN imaging [13], and ESNF31 for ad-
renal glands [15]. MB was used as purchased without 
further treatment (31.3 mM), and all other NIR 
fluorophores were dissolved in dimethyl sulfoxide 
(DMSO) as a 10 mM stock solution. 
Optical Property Measurements: Optical prop-
erties of NIR fluorescent contrast agents were meas-
ured in 100% fetal bovine serum (FBS) supplemented 
with 50 mM HEPES, pH 7.4. The quantum yield (QY) 
of 700 nm NIR fluorophores was measured using 
Oxazine 725 (Sigma-Aldrich) in ethylene glycol (QY = 
19%) was used as a calibration standard under condi-
tions of matched absorbance at 655 nm [22], while 
indocyanine green (ICG) in DMSO (QY = 13%) was 
used for the QY of 800 nm NIR fluorophores with a 
matched absorbance at 770 nm [23]. For in vitro optical 
property measurements, online fiberoptic HR2000 
absorbance (200-1100 nm) and USB2000FL fluores-
cence (350-1000 nm) spectrometers (Ocean Optics, 
Dunedin, FL) were used. NIR excitation was provided 
by 5 mW of 655 nm red laser pointer (Opcom Inc., 
Xiamen, China) and 8 mW of 765 nm NIR laser diode 
light source (Electro Optical Components, Santa Rosa, 
CA) coupled through a 300 µm core diameter, NA 0.22 
fiber (Fiberguide Industries, Stirling, NJ). In silico 
calculations of the distribution coefficient (logD at pH 
7.4) and 3D minimized structures were calculated 
using Marvin and JChem calculator plugins (Che-
mAxon, Budapest, Hungary).  
Animal Models: Animals were housed in an 
Association for Assessment and Accreditation of La-
boratory Animal Care (AAALAC)-certified facility 
and were studied under the supervision of Beth Israel 
Deaconess Medical Center’s Institutional Animal Care 
and Use Committee (IACUC) in accordance with ap-
proved institutional protocols #101-2011 for rodents 
and #034-2013 for pigs. Male CD-1 mice (n = 42) av-
eraging 21 g and male Sprague-Dawley rats (n = 6) 
averaging 262 g (Charles River Laboratories, Wil-
mington, MA) were anaesthetized with 100 mg/kg 
ketamine and 10 mg/kg xylazine intraperitoneally 
(Webster Veterinary, Fort Devens, MA) and a midline 
laparotomy was performed to expose the viscera. 
Female Yorkshire pigs (n = 12) averaging 35.5 kg 
(E.M. Parsons and Sons, Hadley, MA) were induced 
with 4.4 mg/kg intramuscular Telazol (Fort Dodge 
Laboratories, Fort Dodge, IA) and intubated; anes-
thesia was maintained with 2% isoflurane (Baxter 
Healthcare, Deerfield, IL). Following anesthesia, a 
14-G central venous catheter was inserted into the 
external jugular vein, and saline was administered as 
needed. A midline laparotomy and a left trans-rectus 
incision were performed for satisfactory intraopera-
tive imaging. Electrocardiogram, heart rate, pulse 
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oximetry, and body temperature were monitored 
during the experiment.  
NIR Fluorescence Imaging System: The du-
al-NIR channel FLARE imaging system has been de-
scribed in detail previously [17,24]. In this study, 670 
nm excitation and 760 nm excitation fluence rates 
used were 4.0 and 11.0 mW/cm2, respectively, with 
white light (400 to 650 nm) at 40,000 lx. Color image 
and 2 independent channels (700 nm and 800 nm) of 
NIR fluorescence images were acquired simultane-
ously with custom software at rates up to 15 Hz over a 
15-cm diameter field of view (FOV). In the color-NIR 
merged images, 700 nm NIR fluorescence and 800 nm 
fluorescence were pseudo-colored red and lime green, 
respectively. The imaging system was positioned at a 
distance of 18 inches from the surgical field. Camera 
exposure time and normalization were held constant 
for each experiment. 
Intraoperative Pancreas Imaging in Mice, Rats, 
and Pigs: For initial in vivo screening, 25 nmol of 
T700-H and T700-F were injected intravenously into 
CD-1 mice 4 h prior to imaging (n = 3 per each fluor-
ophore). As a control, 120 nmol (1.5 mg/kg) of MB 
was injected 15 min prior to imaging (n = 3) [11]. In 
the dose optimization study, we injected 5 different 
doses of T700-F (0, 10, 25, 50, and 100 nmol) and im-
ages were taken at 4 h post-injection (n = 3 per each 
dose). For the kinetics study, we injected 25 nmol of 
T700-F intravenously and observed the fluorescent 
signal of pancreas at 6 different time points (0, 1, 2, 4, 
8, and 24 h) (n = 3 per each time point). For rat studies, 
1.2 µmol of MB (1.5 mg/kg) and 100 nmol of T700-F 
were injected intravenously 15 min and 4 h prior to 
imaging, respectively (n = 3 each NIR fluorophore). 
All NIR fluorophores except for MB were diluted into 
5% dextrose in water (D5W) before injection, and 100 
µL was injected into mice and 500 µL was injected into 
rats, respectively.  
For large animal swine studies, 164 µmol (1.5 
mg/kg) of MB and 2.5 µmol of T700-F were injected 
intravenously. We observed the fluorescent signals of 
viscera for 1 h post-injection, calculated a sig-
nal-to-background ratio (SBR) at 6 different time 
points (0, 3, 5, 15, 30, and 60 min), and compared the 
performance (n = 3 per each fluorophore). Next, we 
performed kinetics study using 2.5 µmol of T700F, 
and images were recorded at 11 different time points 
(0, 15, 30, 60, 90, 120, 180, 240, 300, 360, and 480) (n = 
3). Finally, we tested dual-channel imaging of pan-
creas with surrounding vital tissues and organs in-
cluding arteries, kidneys, pan lymph nodes (PLNs), 
and adrenal glands: 2 µmol of ZW800-1 for NIR arte-
riography and kidney imaging, 1 µmol of ZW800-3C 
for PLN imaging, and 2 µmol of ESNF31 for adrenal 
gland imaging (n = 1 for each study). The NIR angi-
ography was recorded immediately after a single in-
travenous injection of ZW800-1 and kidneys were 
imaged 2 h post-injection. The PLN imaging was 
performed 4 h post-injection, while adrenal glands 
were imaged at 30 min post-injection. These imaging 
times were chosen based on prior optimization 
[13,15,25]. Each NIR agent was diluted into 10 mL of 
D5W prior to injection. 
NIR Fluorescence Microscopy: For histological 
evaluations, pancreatic tissues were resected from rats 
after scheduled imaging using MB and T700-F, em-
bedded in Tissue-Tek OCT compound (Fisher Scien-
tific, Pittsburgh, PA), and flash frozen in liquid ni-
trogen. Tissue was cryosectioned at 10 µm intervals 
and observed using a NIR fluorescence microscope. 
Consecutive sections were stained with hematoxylin 
and eosin (H&E). NIR fluorescence microscopy was 
performed on a 4 filter-set Nikon Eclipse TE300 
epifluorescence microscope to confirm the fluores-
cence of the pancreas as previously described [26,27]. 
The microscope was equipped with a 100 W mercury 
light source, NIR-compatible optics, and a 
NIR-compatible 4X, 10X, 20X, and 40X Plan Fluor ob-
jective lens (Nikon, Melville, NY). Custom filter sets 
(Chroma Technology Corporation, Brattleboro, VT) 
composed of a 650 ± 22 nm excitation filter and a 710 ± 
25 nm emission filter were used to detect the pancreas 
fluorescence signal. Images were acquired on an Or-
ca-AG (Hamamatsu, Bridgewater, NJ) and QImaging 
12-bit camera for color imaging (Surrey, BC, Canada). 
Image acquisition and analysis was performed using 
iVision software (BioVision Technologies, Exton, PA).  
Quantitation and Statistical Analysis: The flu-
orescent intensity (FI) of a region of interest (ROI) 
over the pancreas, rectus abdominis muscle, liver, 
spleen, duodenum, lymph nodes, and kidneys were 
quantified using custom FLARE software. The per-
formance metric for this study was SBR. SBR = FI of 
ROI / background (BG) intensity. The rectus abdom-
inis muscles, liver, spleen, duodenum, lymph nodes, 
and kidneys were used as BG compared to the signal 
in the pancreas to yield pancreas-to-muscle ratio 
(Pa/Mu), pancreas-to-liver ratio (Pa/Li), pancre-
as-to-spleen ratio (Pa/Sp), pancreas-to-duodenum 
ratio (Pa/Du), pancreas-to-lymph node ratio 
(Pa/LN), and pancreas-to-kidney ratio (Pa/Ki). At 
least 3 animals were analyzed for SBR at each time or 
dose point. Results were presented as mean ± stand-
ard deviation (SD). The statistical analysis was per-
formed using the Unpaired T test between two groups 
and a one-way ANOVA followed by Tukey’s multiple 
comparisons test between multiple groups. A P value 
of less than 0.05 was considered significant: *P < 0.05, 
**P < 0.01, and ***P < 0.001.  
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Results 
Optical properties of NIR fluorescent contrast 
agents. The chemical structure, absorbance, and flu-
orescence spectra for MB, T700-H, T700-F, ZW800-1, 
ZW800-3C, and ESNF31 are shown in Figure 1. Addi-
tionally, Table 1 details the optical properties of each 
NIR fluorophore in 100% serum. T700 fluorophores 
have 2-3 fold higher extinction coefficient and more 
than 3-fold higher QY compared to MB, which re-
sulted in a total of 8-fold higher molecular brightness 
(Table 1). To summarize, MB, T700-H, and T700-F 
exhibited optical properties compatible with NIR flu-
orescence channel #1 (700 nm) of the FLARE imaging 
system, while ZW800-1, ZW800-3C, and ESNF31 were 
imaged using NIR fluorescence channel #2 (800 nm), 
which permits simultaneous, real-time, dual-channel 
intraoperative imaging.  
 
 
 
Figure 1. Chemical Structure and Optical Properties of NIR Fluorophores. Chemical structure, molecular weight (MW), and logD at pH 7.4 were depicted using MarvinSketch 
(ChemAxon). Absorbance (Abs) and fluorescence (FL) emission spectra were measured in 100% fetal bovine serum at pH 7.4. a) 700 nm NIR Fluorophores. b) 800 nm NIR 
Fluorophores.  
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Table 1. Optical properties of NIR fluorophores in 100% serum supplemented with 50 mM HEPES (pH 7.4). 
Optical Property MB T700-H T700-F ZW800-1 ZW800-3C ESNF31 
FLARE Imaging Channel 700 nm NIR (Channel #1) 800 nm NIR (Channel #2) 
Extinction Coefficient (M-1cm-1) 49,500 147,000 123,000 249,000 309,000 135,000 
Absorbance Maximum (nm) 665 648 651 772 774 803 
Emission Maximum (nm) 688 670 665 788 789 814 
Quantum Yield (%) 9.6 30.4 29.9 15.1 16.1 10.8 
Molecular Brightness (M-1cm-1) 4,752 44,688 36,777 37,599 49,749 14,580 
In silico calculations of logD at pH 7.4 and total polar surface area were calculated using Marvin and JChem calculator plugins (ChemAxon, Budapest, Hungary). 
 
 
Initial in vivo screening in mice. Our NIR 
fluorophore library consists of over 300 novel com-
pounds. Initial screening in mice revealed 2 pen-
tamethine indocyanine fluorophores, T700-H and 
T700-F, with unusually high uptake in pancreas 
(Supplementary Material: Figure S1). T700-F showed 
a stronger pancreas signal and higher contrast to 
surrounding organs, such as duodenum, spleen, and 
liver. Both, however, also had strong kidney signal 
due to renal elimination. We then compared these two 
NIR fluorophores to clinically available MB in mice 
and re-measured SBR. As shown Figure 2A, T700-F 
showed the highest uptake in pancreas compared to 
others, and a significant improvement in SBR was 
found when compared with MB, which was injected 
at a 4-fold higher dose and exhibited a 10-fold shorter 
retention time [11]. Because T700-F demonstrated the 
highest SBR, we explored its dose optimization and 
kinetics, and expanded the study to 2 additional spe-
cies, rats and pigs. 
Kinetics and dose optimization of T700-F in 
mice. To optimize the best imaging time for pancreas 
(Pa), we injected 25 nmol of T700-F intravenously into 
CD-1 mice and measured the SBR of pancreas and 
surrounding tissues over the course of 24 h. As shown 
in Figure 2B, the highest SBR relative to liver (Li), 
spleen (Sp), and duodenum (Du), was achieved at 4 h 
post-injection although the background signal de-
creased continuously over time, the fluorescence sig-
nal of pancreas also diminished significantly after 4 h 
(Figure 2D). Therefore, dose optimization was per-
formed at 4 h post-injection. Of note, no adverse reac-
tions were encountered over the 24 h observation pe-
riod. 
For dose-optimization, we injected 5 different 
doses of T700-F (0, 10, 25, 50, and 100 nmol) into CD-1 
mice, and images were acquired at 4 h post-injection. 
Signals in pancreas (Pa) increased proportionally to 
dose, but background signal in surrounding organs, 
including spleen (Sp) and duodenum (Du), rose sig-
nificantly above the 25 nmol dose (Figure 2D). There 
was no significant difference in SBR of (Pa/Sp) and 
(Pa/Du) among 25 – 100 nmol groups (Figure 2C).  
Intraoperative pancreas imaging and histology 
in rats. We compared T700-F with MB in SD rats by 
injecting 100 nmol of T700-F and 1.2 µmol (1.5 mg/kg) 
of MB, respectively (Figure 3A). Although MB high-
lighted the pancreas immediately after a single intra-
venous injection, the fluorescent signal in pancreas 
diminished rapidly after 15 min. Conversely, T700-F 
showed strong pancreas signal and low background 
uptake even at 4 h post-injection. After intraoperative 
imaging, we resected the pancreas and performed 
histological analysis (Figure 3B). NIR fluorescence 
microscopy confirmed 700 nm fluorescence signal in 
the resected pancreatic tissues. Both fluorophores 
accumulated in the intracellular space: T700-F stained 
both the exocrine pancreas (acini; AC) cells and islets 
of Langerhans (IL), while MB exhibited proportion-
ally higher islet uptake. 
In vivo pancreas imaging in pigs. To confirm 
that small animal results were not species-dependent, 
we performed pancreas imaging in 35 kg Yorkshire 
pigs using 164 µmol (1.5 mg/kg) of MB and 2.5 µmol 
of T700-F. We administered more than a 65-fold 
higher dose of MB, however, pancreatic contrast di-
minished rapidly over time while T700-F showed an 
extremely strong pancreas signal (Figure 4A). Alt-
hough the initial uptake of T700-F in spleen was 
higher than in the pancreas, the fluorescence signal in 
spleen decreased gradually and was negligible at 60 
min post-injection. Adequate SBR (Pa/Mu) of MB was 
only seen for the initial 15 min and the SBR decayed 
by 60 min to almost the pre-injection level (Figure 4B). 
In contrast, T700-F maintained its SBR (Pa/Mu) of ≈ 
5.0 for 60 min without detectable decrease and there 
was a significant difference in SBR (Pa/Mu) for 1 h 
between MB and T700-F. We further investigated the 
kinetics of T700-F for up to 8 h by comparing signals 
in the pancreas (Pa) with surrounding tissue and or-
gans such as muscle (Mu), spleen (Sp), lymph nodes 
(Ln), and kidneys (Ki) (Figure 4C). Overall T700-F 
showed relatively high SBRs for up to 8 h without 
significant decrease in the pancreatic signal except for 
the SBR (Pa/Ki). Of note, no adverse reactions were 
encountered over the 8 h observation period. 
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Figure 2. Quantitative Evaluation of NIR Fluorophore Uptake in Mouse Pancreas: a) SBR (mean ± SD) of pancreas against liver, spleen, and duodenum was compared using 
various NIR fluorophores. b) Quantitative time-course assessment: 25 nmol of T700-F was injected intravenously into CD-1 mice, and SBR (Pa/Li), SBR (Pa/Sp) and SBR (Pa/Du) 
were measured at different time points (T = 0, 1, 2, 4, 8, and 24 h). c) Dose-response curve: 0, 10, 25, 50 and 100 nmol of T700-F were injected intravenously into CD-1 mice, 
and SBR (Pa/Li), SBR (Pa/Sp) and SBR (Pa/Du) were measured at 4 h post-injection. d) Real-time intraoperative imaging of pancreas in different time and doses. Controls were 
injected with D5W alone, and at least 3 animals were used for each data point. Scale bars = 0.5 cm. *P < 0.05, **P < 0.01, and ***P < 0.001. Abbreviations used are: Du, duodenum; 
Li, liver; Pa, pancreas (arrow); Sp, spleen; St, stomach; Pa/Li, pancreas-to-liver ratio; Pa/Sp, pancreas-to-spleen ratio; Pa/Du, pancreas-to-duodenum ratio. All NIR fluorescence 
images have identical exposure times and normalizations. 
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Figure 3. Intraoperative Pancreas Imaging in SD Rats: a) 1.2 µmol of MB and 100 nmol of T700-F were injected intravenously 15 min and 4 h prior to imaging, respectively (n 
= 3). Abbreviations used are: Bl, bladder; Du, duodenum; In, intestine; Ki, kidney; Li, liver; Pa, pancreas; Sp, spleen. Arrows indicate pancreas and arrowheads indicate auto-
fluorescence of food in lumen of intestine. Scale bars = 1 cm. All NIR fluorescence images have identical exposure times and normalizations. b) Histological analysis: Consecutive 
sections from rat pancreas stained with H&E or unstained were observed using an NIR fluorescence microscope. Abbreviations used are: Ac, acinus; IL, islets of Langerhans; PD, 
pancreatic duct. Scale bars = 300 µm. All NIR fluorescence images for each condition have identical exposure times and normalizations.  
 
 Theranostics 2015, Vol. 5, Issue 1 
 
http://www.thno.org 
8 
 
Figure 4. Intraoperative Pancreas Imaging in Pigs: a) 164 µmol of MB and 2.5 µmol of T700-F were injected intravenously into 35 kg Yorkshire pigs, and images were recorded 
over the course of 60 min (n = 3). Abbreviations used are: Du, duodenum; Ki, kidney; Li, liver; LN, lymph node; Pa, pancreas. All NIR fluorescence images have identical exposure 
times and normalizations. b) SBR (mean ± SD) comparison between MB and T700-F: SBR (Pa/Mu) was measured at different time points. ***P < 0.001. Statistical analysis between 
MB and T700-F was performed using unpaired t test. c) Quantitative time-course assessment of SBR (mean ± SD) for pancreas and surrounding organs/tissues were measured 
after 2.5 µmol of T700-F injection over the course of 8 h (n = 3). Abbreviations used are: Pa/Mu, pancreas-to-muscle ratio; Pa/Sp, pancreas-to-spleen ratio; Pa/LN, pancre-
as-to-lymph node ratio; Pa/Ki, pancreas-to-kidney ratio. Scale bars = 1 cm. All NIR fluorescence images have identical exposure times and normalizations. 
 
Simultaneous dual-channel imaging of pan-
creas for image-guided abdominal surgery. Since the 
proximity of the pancreas to surrounding tissues and 
organs, such as arteries, lymph nodes, kidneys, and 
adrenal glands, is the main cause of intraoperative 
pancreatic injury, we explored simultaneous du-
al-channel imaging of pancreas. With the assistance of 
already developed 800 nm emitting NIR fluorophores 
[13,15,21], the FLARE imaging system enabled 700 nm 
and 800 nm NIR fluorescence imaging simultaneously 
in real time.  
 To identify blood vessels, ZW800-1 was injected 
intravenously into pig 4 h after injection of T700-F. As 
shown in Figure 5, we could visualize not only im-
portant arteries in gastrointestinal surgery such as the 
common hepatic artery, left gastric artery, and splenic 
artery, but also extremely small vessel branches from 
the common hepatic artery. 
Because ZW800-1 is cleared from the body via 
renal excretion, we continuously imaged kidneys and 
found that kidney signal from ZW800-1 was highest 
at 2 h post-injection [21]. As shown in Figure 5, this 
permitted unambiguous identification of the bound-
ary of pancreas from the kidney. 
In subsequent experiments, we imaged peripan-
creatic lymph nodes by injecting ZW800-3C along 
with T700-F 4 h prior to imaging [13]. Lymph nodes 
were clearly visualized even when obscured by over-
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lying pancreatic tissue, with the color merged image 
showing all desired surgical landmarks on one screen.  
Finally, for dual-channel imaging of pancreas 
and adrenal glands, T700-F was injected 4 h prior to 
imaging, followed by injecting ESNF31 intravenously 
in the same pig 30 min prior to imaging [15]. Pancreas 
and adrenal glands were readily imaged using the 700 
nm and 800 nm NIR channels, respectively. This du-
al-channel imaging permitted the pancreas to be dis-
tinguished from peripancreatic lymph nodes and the 
adrenal gland rather easily. 
Discussion 
Recent technical advances in abdominal surgery 
have made complex procedures safer and shorter. 
However, pancreas-related complications after gas-
trectomy with radical lymphadenectomy including 
peripancreatic lymph nodes resection, splenectomy, 
adrenalectomy, and nephrectomy remain unaccepta-
bly high [1,2,9,10]. Even with a magnified view pro-
vided by laparoscopy, it remains difficult to avoid 
pancreatic injury because of relatively poor contrast 
between pancreas and surrounding tissues and or-
gans, and the inability of visible light to penetrate 
through blood and overlying tissue. NIR light has the 
potential to solve this problem because it can pene-
trate 5-8 mm into living tissue [28] and specific NIR 
contrast agents can be used to highlight specific 
anatomy. Importantly, NIR fluorescence imaging 
systems are now widely available for both open and 
minimally-invasive surgery. 
 
 
Figure 5. Simultaneous Dual Channel Imaging of Pancreas and Surrounding Tissues and Organs: 2.5 µmol of T700-F was injected intravenously for pancreas imaging 4 h prior to: 
1st row: NIR angiography with 2 µmol intravenous injection of ZW800-1 immediately prior to imaging. 2nd row: Kidney imaging with 2 µmol intravenous injection of ZW800-1 
30 min prior to imaging. 3rd row: Pan lymph node imaging with 1 µmol intravenous injection of ZW800-3C 4 h prior to imaging. 4th row: Adrenal gland imaging with 2 µmol 
intravenous injection of ESNF31 30 min prior to imaging (n = 3 pigs). Shown are color image, 700 nm NIR fluorescence, 800 nm NIR fluorescence, and a merged image of the 
three. For the merged image, FLARE™ channel #1 (700 nm) is pseudo-colored in red and channel #2 (800 nm) in green. Abbreviations used are: AG, adrenal gland; CHA, 
common hepatic artery; Du, duodenum; In, intestine; Ki, kidney; Li, liver; LGA, left gastric artery; Pa, pancreas; Sp, spleen; St, stomach; SPA, splenic artery. Arrowheads indicate 
tiny branch from artery (1st row), kidney (2nd row), pan lymph nodes (3rd row), or adrenal gland (4th row). Scale bars = 1 cm. All NIR fluorescence images have identical exposure 
times and normalizations. 
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MB is a NIR fluorophore that we previously 
demonstrated can highlight the pancreas, and inter-
estingly, insulinoma, however, it has relatively poor 
optical properties and short retention in the pancreas 
[11]. Out of over 300 candidates, T700-F showed sig-
nificantly high uptake in pancreas and low back-
ground tissue uptake. Furthermore, its retention in 
pancreas was over 8 h, making this agent potentially 
useful in complex abdominal surgeries including 
laparoscopic operations (Figure 4C) [29]. Although 
the mechanism of specific pancreas uptake and reten-
tion of T700-F is currently unknown, it appears that 
the physicochemical properties of the substituted 
pentamethine play a key role for targeting. T700-F 
differs from T700-H by only 2 fluorine atoms, yet 
these atoms result in significantly improved pancreas 
selectivity.  
There are some limitations, though, to the pre-
sent study. First, our prototype pancreas-targeted 
compound T700-F emits at 700 nm where autofluo-
rescence exists from fecal contents. A thorough bowel 
cleansing is therefore important. Development of an 
800 nm version, which would solve this problem, is 
ongoing. Second, T700-F shows nonspecific uptake in 
kidneys, spleen, and lymph nodes and kidney, espe-
cially, has a higher signal than pancreas. However, as 
shown in Figure 5, this limitation is easily overcome 
by a low-dose injection of ZW800-1, which permits 
unambiguous separation of kidney from pancreas. 
Because first-in-human trials of ZW800-1 are immi-
nent, it should be available for this application in the 
near future. Third, T700-F will require the same reg-
ulatory path as any drug prior to human use. Despite 
these limitations, this study lays the foundation for 
real-time intraoperative pancreas imaging during 
complex abdominal surgeries. 
Supplementary Material 
Fig.S1. http://www.thno.org/v05p0001s1.pdf 
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